問卷

TPIDB > Search Result

Search Result

篩選

List

23Cases

2025-11-01 - 2033-12-31

Phase III

Not yet recruiting
A phase III, open-label, randomized, multicenter, parallel-group trial evaluating the efficacy and safety of first-line trastuzumab deruxtecan combined with rilvegostomig or volrustomig versus pembrolizumab plus chemotherapy in locally advanced, unresectable, or metastatic HER2-overexpressing non-squamous NSCLC (DESTINY-Lung07).
  • Condition/Disease

    Locally advanced unresectable or metastatic HER2-overexpressing non-squamous non-small cell lung cancer

  • Test Drug

    Trastuzumab Deruxtecan(AZD4552 DS-8201A)

Participate Sites
9Sites

Recruiting9Sites

2025-08-01 - 2031-12-31

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-01-01 - 2040-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-04-17 - 2026-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-01-22 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2020-09-15 - 2025-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting6Sites

Terminated6Sites

2022-01-01 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2021-01-01 - 2024-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-05-01 - 2024-04-15

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting9Sites

2020-11-02 - 2024-04-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

1 2 3